Physician profile
Seth Strope
NPI 1427109248
$26,569.58
in general payments reported to CMS, 2019-2025
47 companies · $12K in 2025
The $12K reported for 2025 was more than what 95% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,318 · 2020: $1,789 · 2021: $898 · 2022: $1,813 · 2023: $1,933 · 2024: $1,846 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,260 · Consulting Fee: $5,174 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,630 · Travel and Lodging: $546 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,260.19 |
| Consulting Fee | $5,173.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,630.00 |
| Travel and Lodging | $546.48 |
| Education | $140.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $8,975.73 | 2020-2025 | Carvykti, Rybrevant, Erleada |
| Merck Sharp & Dohme LLC | $7,663.05 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $1,698.88 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $1,502.90 | 2019-2025 | Erleada |
| Ferring Pharmaceuticals INC. | $743.78 | 2024-2025 | Adstiladrin |
| Boston Scientific Corporation | $680.58 | 2019-2025 | Moses 550 Dfl, Spaceoar Vue System - 10ml, Lumenis Pulse 120h |
| Urogen Pharma, INC. | $647.70 | 2021-2025 | Jelmyto |
| Sumitomo Pharma America, INC. | $371.43 | 2023-2025 | Orgovyx, Gemtesa |
| Astellas Pharma US INC | $341.19 | 2019-2024 | Myrbetriq, Xtandi |
| Dendreon Pharmaceuticals LLC | $329.24 | 2021-2025 | Provenge |
| Astrazeneca Pharmaceuticals Lp | $325.85 | 2021-2025 | Lynparza |
| Procept Biorobotics Corporation | $322.70 | 2024-2025 | Aquabeam System |
| Bayer Healthcare Pharmaceuticals INC. | $268.52 | 2019-2025 | |
| Accord Healthcare, INC. | $253.92 | 2023-2025 | |
| Cook Medical LLC | $241.79 | 2019-2025 | Cook |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Strope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.